CapForce IBD 50 ETF
FFTY
86 hedge funds and large institutions have $138M invested in CapForce IBD 50 ETF in 2019 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 26 increasing their positions, 26 reducing their positions, and 18 closing their positions.
3,680% more call options, than puts
Call options by funds: $378K | Put options by funds: $10K
71% more capital invested
Capital invested by funds: $80.6M → $138M (+$57.2M)
17% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 18
6.74% more ownership
Funds ownership: 23.55% → 30.29% (+6.7%)
4% more funds holding
Funds holding: 83 → 86 (+3)
0% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 26
Top Buyers
Top Sellers
FFTY Hedge Fund Activity: Q1 2019 in Review
86 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in CapForce IBD 50 ETF (FFTY) for Q1 2019, worth a combined $138M — up 71% from $80.6M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new FFTY positions and 18 closed out — a net gain of 3 holders — while 26 added to existing stakes and 26 trimmed.
The largest buyer was Wells Fargo, adding an estimated $20M. The largest seller was Tower Research Capital (TRC), cutting an estimated $1.95M.
- 86 institutional investors held CapForce IBD 50 ETF (FFTY) as of Q1 2019, up from 83 in Q4 2018.
- Funds reported $138M of CapForce IBD 50 ETF stock for Q1 2019, up 71% quarter-over-quarter.
- 21 funds opened new CapForce IBD 50 ETF positions in Q1 2019 and 18 closed out, a net change of +3 holders.
- The largest CapForce IBD 50 ETF buyer in Q1 2019 was Wells Fargo, an estimated $20M added.
- The largest CapForce IBD 50 ETF seller in Q1 2019 was Tower Research Capital (TRC), an estimated $1.95M sold.
Based on aggregated 13F filings for Q1 2019.